探索 levetiracetam 如何减轻毒性并改善记忆障碍
Ahmad H Alhowail1, Abeer M Alharbi1
1Department of Pharmacology and Toxicology, College of Pharmacy, Qassim University, Buraydah, Saudi Arabia.
Frontiers in pharmacology
|September 29, 2025
概括
一种抗药物Levétiracetam (LEV) 通过减少神经炎症和氧化应激减轻认知障碍,显示出有前途. 需要进一步的临床研究来确认其在治疗之外的疗效.
科学领域:
- 神经科学是一个神经科学.
- 药理学 药理学是指药理学的学科.
- 老年学是指老年学的学科.
背景情况:
- 认知障碍会影响日常功能和生活质量,从轻度衰退到严重痴呆症.
- 它不成比例地影响老年人和癌症幸存者.
- 病理生理机制包括神经炎症,氧化应激,突触可塑性受损和神经元亡.
研究的目的:
- 综合当前关于认知障碍机制的知识.
- 评估现有的测量和预防策略及其局限性.
- 批判性地检查 levetiracetam (LEV) 在缓解认知衰退方面的潜在疗效.
主要方法:
- 文献综述综合现有临床和实验数据.
- 对LEV的作用机制的分析,包括突触囊泡蛋白2A的结合.
- 评估LEV的抗炎和抗氧化特性.
主要成果:
- 通过选择性结合到突触囊泡蛋白2A和神经递质调制,LEV显示出神经保护的潜力.
- 莱维具有抗炎和抗氧化特性.
- 目前的证据表明,LEV可能会减轻认知障碍.
结论:
- 除了其抗用途之外,LEV是对认知障碍的有希望的治疗候选者.
- 它的神经保护作用与其抗炎和抗氧化作用有关.
- 进一步的临床研究至关重要,以验证LEV在治疗认知衰退中的有效性.
相关概念视频
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
827
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
827
Antiepileptic Drugs: Potassium Channel Activators
635
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Ezogabine has gained approval as an adjunctive treatment...
635
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
560
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
560
Antiepileptic Drugs: Glutamate Antagonists
898
Glutamate is a fundamental neurotransmitter in the central nervous system, playing a vital role in neuronal communication and various cognitive processes. Glutamate stands as the principal excitatory neurotransmitter in the brain. Its presence is crucial for the communication between neurons, underpinning essential processes such as synaptic transmission, neuronal excitability, and plasticity. These functions are vital for higher-order cognitive processes, including learning and memory. The...
898
Antiepileptic Drugs: GABAergic Pathway Potentiators
1.2K
γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
1.2K
Alzheimer's Disease: Treatment
824
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
824


